Compare Apple Inc (AAPL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs TransMedics Group Inc — how do they compare? Apple Inc trades at $302.01 (market cap $4.45T), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Apple Inc is far larger — about 1435.5× TransMedics Group Inc's market cap, and Apple Inc pays a 0.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AAPL | TMDX | |
|---|---|---|
Market Cap | $4.45T | $3.10B |
Volume | 100,358,844 | — |
Sector | Technology | Technology |
52-Week High | $340.08 | $150.42 |
52-Week Low | $224.90 | $61.99 |
Enterprise Value | $4.47T | $3.49B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.42, down 2.22% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 26.91% net income margin and consistent earnings beats. Recent news highlights Apple's leadership in smartphone shipments and AI potential through its 2.5 billion active devices, though it faces challenges from union disputes and potential earnings pressure.
Outlook remains positive with a consensus price target of $337.63, implying 12% upside. Risks include weaker iPhone sales, regulatory scrutiny from EU fines, and competitive pressures. Analyst sentiment is bullish (63.64% buy ratings), but technical weakness and near-term headwinds warrant caution.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
